



**UNITED STATES DEPARTMENT OF COMMERCE**  
**Patent and Trademark Office**  
ASSISTANT SECRETARY AND COMMISSIONER  
OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

#27

FEB 27 1992

Ronald L. Wilson, Director  
Health Assessment Policy Staff  
Office of Health Affairs (HFY-20)  
Food and Drug Administration  
5600 Fisher's Lane, Room 11-44  
Rockville, MD 20857

Re: Zithromax  
FDA Docket No. 92E - 0027

Dear Mr. Wilson:

Transmitted herewith is a copy of the application for patent term extension of U.S. Patent No. 4,517,359 issued May 14, 1985. The application was filed on December 23, 1991, under Title II of Public Law 98 - 417, the Drug Price Competition and Patent Term Restoration Act of 1984.

The patent claims a product that was subject to regulatory review under the Federal Food, Drug and Cosmetic Act. Subject to final review, the subject patent is considered to be eligible for patent term restoration. Thus, a determination by your office on the applicable regulatory review period is necessary. Accordingly, notice and a copy of the application are provided pursuant to 35 USC § 156 (d) (2) (A).

*C.E. Van Horn*

Charles E. Van Horn  
Patent Policy & Programs Administrator  
Office of the Assistant Commissioner for Patents

cc: J. Trevor Lumb  
Pfizer Inc.  
Patent Department  
Eastern Point Road  
Groton, CT 06340